The U.S. Army Medical Research Acquisition Activity (USAMRAA) has awarded The Lundquist Institute (TLI) a four-year grant totaling $2,623,234. The research project is led by Dr. Harry Rossiter, an investigator at TLI and Professor at the David Geffen School of Medicine at UCLA. The project aims to develop wearable multiplex biosensors to monitor exacerbation risk in chronic obstructive pulmonary disease (COPD).

The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (TLI) has announced changes to its Board of Directors. The organization welcomes four distinguished incoming members and thanks the outgoing members for their invaluable contributions.

The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (TLI) has announced that The California Institute for Regenerative Medicine (CIRM), one of the world’s largest institutions dedicated to regenerative medicine, has awarded $1.5 million to TLI Investigator Denise Al Alam, PhD, to support research that aims to understand lung disease in individuals with Trisomy 21 (also known as Down Syndrome). Although Trisomy 21 impacts multiple organ systems, respiratory complications are a significant cause of death in children and adults with this genetic condition.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of the National Institutes of Health, has granted Eiji Yoshihara, PhD, a principal investigator at The Lundquist Institute (TLI) and assistant professor at the David Geffen School of Medicine at UCLA, a five-year grant totaling $3 million. This prestigious NIH R01 grant, known for its rigorous peer-review process, is dedicated to advancing stem cell therapy research for treating diabetes.